AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17324008 — intervention group
Group type: EXPERIMENTAL
Intervention: ISA 247 (mid dose)
Number of subjects: 193
Study 17324008 — intervention group
Group type: COMPARATOR
Intervention: Ciclosporin
Number of subjects: 193
Study 12959960 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 7
Study 12959960 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11773574 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200,000 IU, half that dose if <12 months)
Number of subjects: 687
Study 11773574 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 687
Study 11773574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 687
Study 8590608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.35 g/kg
Number of subjects: 9
Study 8590608 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0.55 g/kg
Number of subjects: 9
Study 8590608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2800986 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 7 micrograms/kg plus methohexitone plus O2/air (Group A7)
Number of subjects: 89
Study 2800986 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms/kg plus methohexitone plus O2/air (Group A15)
Number of subjects: 89
Study 2800986 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5 mg/kg plus N2O/O2 (Group P, reference group)
Number of subjects: 89
Study 50014 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitation treatment approach
Number of subjects: 12
Study 50014 — intervention group
Group type: COMPARATOR
Intervention: Functional treatment approach
Number of subjects: 12
Study 30932317 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14, 2.5 × 10^9 CFUs, once daily)
Number of subjects: 304
Study 30932317 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 304
Study 30932317 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 304
Study 30624674 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNSs) containing 20 mg Fe/d until 6 mo postpartum, and SQ-LNSs for infants from 6 to 18 mo of age (LNS)
Number of subjects: 1320
Study 30624674 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-quantity lipid-based nutrient supplements (SQ-LNSs)
Number of subjects: 1320
Study 30624674 — intervention group
Group type: COMPARATOR
Intervention: Iron (60 mg/d) and folic acid (IFA)
Number of subjects: 1320
Study 30624674 — intervention group
Group type: COMPARATOR
Intervention: Multiple micronutrients (MMN) containing 20 mg Fe/d until 6 mo postpartum
Number of subjects: 1320
Study 27334706 — intervention group
Group type: EXPERIMENTAL
Intervention: Comet
Number of subjects: 749
Study 27334706 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years
Number of subjects: 749
Study 27334706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cope
Number of subjects: 749
Study 27334706 — intervention group
Group type: EXPERIMENTAL
Intervention: Connect
Number of subjects: 749
Study 27334706 — intervention group
Group type: COMPARATOR
Intervention: All programs
Number of subjects: 749
Study 25455432 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD 2.5mg up-titrated to 5mg OaD for 12 weeks
Number of subjects: 590
Study 25455432 — intervention group
Group type: EXPERIMENTAL
Intervention: TAD 5mg OaD for 12 weeks
Number of subjects: 590
Study 25455432 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) OaD for 12 weeks
Number of subjects: 590
Study 23521828 — intervention group
Group type: EXPERIMENTAL
Intervention: IMSI
Number of subjects: 332
Study 23521828 — intervention group
Group type: COMPARATOR
Intervention: ICSI
Number of subjects: 332
Study 21652683 — intervention group
Group type: EXPERIMENTAL
Intervention: CTDa (cyclophosphamide, thalidomide, and dexamethasone)
Number of subjects: 849
Study 21652683 — intervention group
Group type: COMPARATOR
Intervention: MP (melphalan and prednisolone)
Number of subjects: 849
Study 21652683 — intervention group
Group type: EXPERIMENTAL
Intervention: CTDa
Number of subjects: 849
Study 21652683 — intervention group
Group type: EXPERIMENTAL
Intervention: CTDa and MP
Number of subjects: 849
Study 19781409 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 3690
Study 19781409 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 3690
Study 16673054 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 11
Study 16673054 — intervention group
Group type: COMPARATOR
Intervention: Sham group (placebo)
Number of subjects: 11
Study 15155045 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threat/high-efficacy message
Number of subjects: 0
Study 15155045 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 11055004 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular brachytherapy
Number of subjects: 0
Study 9590467 — intervention group
Group type: EXPERIMENTAL
Intervention: Brompheniramine 12 mg twice daily
Number of subjects: 338
Study 9590467 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg once daily
Number of subjects: 338
Study 9590467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 7822454 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-radioactive reverse dot blot hybridization method for typing HPV
Number of subjects: 72
Study 3398891 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus interferon (2 X 10(6) IU per square meter of body-surface area, daily for one week, then three times per week for one year)
Number of subjects: 123
Study 3398891 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (control group)
Number of subjects: 123
Study 3398891 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery plus interferon
Number of subjects: 123
Study 27148916 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoanalytic psychotherapy (PPT)
Number of subjects: 70
Study 27148916 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 70
Study 28873709 — intervention group
Group type: EXPERIMENTAL
Intervention: Yacon syrup (8.74g of FOS/day)
Number of subjects: 0
Study 28873709 — intervention group
Group type: EXPERIMENTAL
Intervention: Yacon syrup incorporated in yogurt
Number of subjects: 0
Study 28873709 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 26964180 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAS
Number of subjects: 60
Study 26964180 — intervention group
Group type: COMPARATOR
Intervention: Sham-TEAS
Number of subjects: 60
Study 26964180 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 22964266 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy (MBT-AS)
Number of subjects: 42
Study 22964266 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 42
Study 20171048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 15 mg/kg
Number of subjects: 60
Study 20171048 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid 10 mg/kg
Number of subjects: 60
Study 20171048 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo (Control)
Number of subjects: 60
Study 20171048 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined autologous and allogenic transfusion (Treatment groups)
Number of subjects: 60
Study 18369313 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg DVS
Number of subjects: 620
Study 18369313 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg DVS
Number of subjects: 620
Study 18369313 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg DVS
Number of subjects: 620
Study 18369313 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg DVS
Number of subjects: 620
Study 18369313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study 17235475 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination preparation (cinnarizine 20 mg and dimenhydrinate 40 mg)
Number of subjects: 2
Study 17235475 — intervention group
Group type: COMPARATOR
Intervention: Betahistine (12 mg betahistinedimesilate)
Number of subjects: 2
Study 12569119 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-enriched milk
Number of subjects: 9
Study 12569119 — intervention group
Group type: EXPERIMENTAL
Intervention: CPP-enriched fermented milk
Number of subjects: 9
Study 12569119 — intervention group
Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 9
Study 10831147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg daily via dry powder inhalation (Rotadisk)
Number of subjects: 77
Study 10831147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 10831147 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 77
Study 9279218 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ppm NO2
Number of subjects: 30
Study 9279218 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 30
Study 8201610 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid blockade (naltrexone)
Number of subjects: 39
Study 8201610 — intervention group
Group type: COMPARATOR
Intervention: Placebo condition
Number of subjects: 39
Study 3310282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin plus tobramycin
Number of subjects: 106
Study 3310282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoperazone
Number of subjects: 106
Study 3310282 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin
Number of subjects: 106
Study 3310282 — intervention group
Group type: COMPARATOR
Intervention: No aminoglycoside
Number of subjects: 106
Study 30166304 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred educational exchange (PCEE) composed of two sessions, one at the bedside before discharge and one by telephone at least 10 days after discharge from hospital in addition to usual care.
Number of subjects: 0
Study 30166304 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study 30166304 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred educational exchange (PCEE)
Number of subjects: 0
Study 26506952 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 30
Study 26506952 — intervention group
Group type: EXPERIMENTAL
Intervention: PErFecTED prostate artery embolization (PAE)
Number of subjects: 30
Study 26506952 — intervention group
Group type: COMPARATOR
Intervention: Original prostate artery embolization (oPAE)
Number of subjects: 30
Study 25403238 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 1477
Study 25403238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1477
Study 23756297 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Cognitive Skills Training (SCST)
Number of subjects: 42
Study 23756297 — intervention group
Group type: COMPARATOR
Intervention: Illness Management Training (Control)
Number of subjects: 42
Study 21389938 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 68
Study 21389938 — intervention group
Group type: COMPARATOR
Intervention: Control (haloperidol)
Number of subjects: 68
Study 21389938 — intervention group
Group type: COMPARATOR
Intervention: No delirium
Number of subjects: 68
Study 18524403 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (five week exercise program including functionally oriented obstacle course, walking exercises, and practice of fall techniques)
Number of subjects: 0
Study 18524403 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific treatment)
Number of subjects: 0
Study 16391172 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg clonidine
Number of subjects: 23
Study 16391172 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1‐mg/h nitroglycerin transdermal patch
Number of subjects: 23
Study 16391172 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 23
Study 14597946 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (uptitrated to 20 mg/d)
Number of subjects: 90
Study 14597946 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (uptitrated to 160 mg/d)
Number of subjects: 90
Study 14597946 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 90
Study 14597946 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 90
Study 10759621 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylanta Lemon Twist
Number of subjects: 73
Study 10759621 — intervention group
Group type: EXPERIMENTAL
Intervention: Mylanta Cherry Crème
Number of subjects: 73
Study 10759621 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox MS Cool Mint
Number of subjects: 73
Study 10759621 — intervention group
Group type: EXPERIMENTAL
Intervention: ES Gaviscon
Number of subjects: 73
Study 10759621 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra strength antacids
Number of subjects: 73
Study 10759621 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphogel
Number of subjects: 73
Study 8752254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium plus oral clodronate, 400 mg/day
Number of subjects: 60
Study 8752254 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral calcium plus oral clodronate, 400 mg/day for 30 days, followed by 60 days of calcium supplement alone (cyclical regimen)
Number of subjects: 60
Study 8752254 — intervention group
Group type: COMPARATOR
Intervention: Oral calcium, 1000 mg/day (control)
Number of subjects: 60
Study 8752254 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous clodronate treatment
Number of subjects: 60
Study 8752254 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclical clodronate treatment
Number of subjects: 60
Study 8752254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate (both cyclical and continuous)
Number of subjects: 60
Study 1561052 — intervention group
Group type: EXPERIMENTAL
Intervention: Chaotic attractors' sequences (Henon, Zaslavskii, Kaplan and Yorke, Lorenz, Gregson, logistic, and Baker transformations)
Number of subjects: 141
Study 1561052 — intervention group
Group type: COMPARATOR
Intervention: Random series (10 realizations)
Number of subjects: 141
Study 4025245 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice group (received information and encouraged to perform coping techniques)
Number of subjects: 51
Study 4025245 — intervention group
Group type: EXPERIMENTAL
Intervention: No-practice group (received information but not encouraged to perform coping techniques)
Number of subjects: 51
Study 4025245 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 51
Study 31668477 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 agonist (PF-06412562) 6 mg
Number of subjects: 120
Study 31668477 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 agonist (PF-06412562) 15 mg
Number of subjects: 120
Study 31668477 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 agonist (PF-06412562) 30 mg
Number of subjects: 120
Study 31668477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31668477 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 agonist (PF-06412562) 6 mg, 15 mg, 30 mg
Number of subjects: 120
Study 30525855 — intervention group
Group type: EXPERIMENTAL
Intervention: Symbiotic supplementation
Number of subjects: 0
Study 30525855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27288381 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen at a dose of 800 mg three times daily
Number of subjects: 0
Study 27288381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24768120 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS + ODT
Number of subjects: 30
Study 24768120 — intervention group
Group type: COMPARATOR
Intervention: Optimal drug therapy (ODT)
Number of subjects: 30
Study 22573476 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (RSV) 10 mg/d
Number of subjects: 262
Study 22573476 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin plus Ezetimibe (RSV/EZT) 10 mg/d
Number of subjects: 262
Study 20552577 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteinizing-hormone-releasing hormone (LHRH) agonists for ovarian function suppression (OFS)
Number of subjects: 0
Study 20552577 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonists
Number of subjects: 0
Study 18156478 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical aqueous 2% lignocaine eardrops
Number of subjects: 63
Study 18156478 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline eardrops)
Number of subjects: 63
Study 15983240 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow sodium tablets
Number of subjects: 40
Study 15983240 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 40
Study 14513587 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser therapy combined with ultrasonic subgingival scaling and root planning (SRP)
Number of subjects: 26
Study 14513587 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 26
Study 10097027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungry-trained subjects (chocolate cravers)
Number of subjects: 29
Study 10097027 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-trained subjects (chocolate cravers)
Number of subjects: 29
Study 10097027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungry-trained subjects (non-cravers)
Number of subjects: 29
Study 10097027 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-trained subjects (non-cravers)
Number of subjects: 29
Study 10097027 — intervention group
Group type: EXPERIMENTAL
Intervention: Hungry-trained subjects (both cravers and non-cravers)
Number of subjects: 29
Study 10097027 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-trained subjects (both cravers and non-cravers)
Number of subjects: 29
Study 8967666 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 mg of rhGH once daily plus placebo twice daily
Number of subjects: 60
Study 8967666 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of rhIGF‐1 twice daily plus placebo once daily
Number of subjects: 60
Study 8967666 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of rhIGF‐1 twice daily plus 1.4 mg of rhGH once daily
Number of subjects: 60
Study 8967666 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily
Number of subjects: 60
Study 1797910 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 0.1%
Number of subjects: 34
Study 1797910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 6275871 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.35 mg kg‐1 with atropine 0.0175 mg kg‐1 in hypercarbia group
Number of subjects: 21
Study 6275871 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.35 mg kg‐1 with atropine 0.0175 mg kg‐1 in hypocarbia group
Number of subjects: 21
Study 6275871 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.35 mg kg‐1 with atropine 0.0175 mg kg‐1 in normocarbia group
Number of subjects: 21
Study 6275871 — intervention group
Group type: COMPARATOR
Intervention: Hypercarbia group
Number of subjects: 21
Study 6275871 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 21
Study 31556653 — intervention group
Group type: EXPERIMENTAL
Intervention: Resource priming condition
Number of subjects: 57
Study 31556653 — intervention group
Group type: COMPARATOR
Intervention: Adherence priming condition
Number of subjects: 57
Study 31556653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (resource priming and adherence priming)
Number of subjects: 57
Study 27573387 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 % trisodium citrate (TSC30 %)
Number of subjects: 464
Study 27573387 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 464
Study 26940892 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT)
Number of subjects: 224
Study 26940892 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 224
Study 26940892 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem or Trazodone (second stage therapy)
Number of subjects: 224
Study 26940892 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy (BT) or Cognitive therapy (CT) (second stage therapy)
Number of subjects: 224
Study 26940892 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep parameters from daily sleep diaries and polysomnography
Number of subjects: 224
Study 26940892 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events, dropout rates, treatment acceptability
Number of subjects: 224
Study 24630938 — intervention group
Group type: EXPERIMENTAL
Intervention: S/S genotype
Number of subjects: 94
Study 24630938 — intervention group
Group type: EXPERIMENTAL
Intervention: L/L genotype
Number of subjects: 94
Study 24630938 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HTTLPR genotype by trait neuroticism interaction
Number of subjects: 94
Study 24630938 — intervention group
Group type: COMPARATOR
Intervention: Control day
Number of subjects: 94
Study 22089461 — intervention group
Group type: EXPERIMENTAL
Intervention: Civamide cream 0.075%
Number of subjects: 695
Study 22089461 — intervention group
Group type: COMPARATOR
Intervention: Civamide cream 0.01% (control)
Number of subjects: 695
Study 19294889 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education program with personal rehabilitation (3 group lectures on health education specific to IPD and 24 half-hour individualized rehabilitation sessions over 8 weeks)
Number of subjects: 44
Study 19294889 — intervention group
Group type: EXPERIMENTAL
Intervention: Group education program with personal rehabilitation
Number of subjects: 44
Study 19294889 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 44
Study 17557972 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention programs (multicomponent strategies, parental involvement)
Number of subjects: 7